Pfizer vaccine deal at $20 a dose sets ceiling for rivals

Bloomberg

22 July 2020 - U.S. agrees to pay Pfizer, BioNTech $1.95 billion on approval.

In signing a $2 billion deal to supply their experimental coronavirus vaccine to the U.S., Pfizer Inc. and BioNTech SE are setting a price ceiling of less than $20 a dose that will impact how much other companies can charge to protect people from COVID-19.

Pfizer’s $19.50 price-point takes into account the “public health requirements during the pandemic,” said Sally Beatty, a Pfizer spokeswoman. The companies are pursuing a two-dose regimen of one of its vaccine candidates, and the roughly $40 course, Beatty said, is “almost 30% less than what others charge for a seasonal flu vaccine.”

Read Bloomberg article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Pricing , Vaccine , Supply , COVID-19